Journals / Retina-Vitreus / 2020 / Cilt: 29 - Sayı: 3

Serum Endocan Levels in Patients with Retinal Vein Occlusion

Pages
238–241
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Statically signifi cant differences in serum level of ESM-1 were observed between the patients and the control group (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: We aimed to evaluate the serum Endocan (endothelial cell-specifi c molecule-1, ESM-1) levels in patients with retinal vein occlusion (RVO) and compare them with those of the control group to determine the correlation with illness activity Materials and Methods: Venous blood samples were obtained from 43 patients with RVO and 43 healthy subjects who attended Atatürk University Medical Faculty Eye Diseases Policlinic between 1 June 2015 and 1 September 2015.
📊
Key Findings & Data:Thirty-one of the 43 patients had branch RVO, and 12 of the patients had central RVO.
💡
Conclusion & Impact:Statically signifi cant differences in serum level of ESM-1 were observed between the patients and the control group (p
🔬Design:Research Article
📍Scope:2015 Verileri
⚙️Variables:Domain Parameters

Abstract

Purpose: We aimed to evaluate the serum Endocan (endothelial cell-specifi c molecule-1, ESM-1) levels in patients with retinal vein occlusion (RVO) and compare them with those of the control group to determine the correlation with illness activity Materials and Methods: Venous blood samples were obtained from 43 patients with RVO and 43 healthy subjects who attended Atatürk University Medical Faculty Eye Diseases Policlinic between 1 June 2015 and 1 September 2015. Thirty-one of the 43 patients had branch RVO, and 12 of the patients had central RVO. Results: The mean age of the patients was 62±10,19, and the mean age of the control group was 60,27±5,53. Twenty-four of the 43 patients (54,5%) suffered from RVO in their right eyes, and 19 of the patients (43,2%) suffered from RVO in their left eyes. No statically signifi cant differences in age and sex were observed between the patients and the control group. All patients had hypertension, and 15 patients had diabetes mellitus. Thirty 30 patients (68,2%) had ischemic-type RVO, 13 patients (29,5%) had nonischemic-type RVO. Thirty-one patients (70,5%) had branch RVO, and 12 patients (27,3%) had central RVO. Statically signifi cant differences in serum level of ESM-1 were observed between the patients and the control group (p

🔖

Cite This Article

ONDAS, O., BAYKAL, O., KOÇER, İ., ATEŞ, O., YILDIRIM, M., ÖZTÜRK, N., GÜL, M. A. (2022). Serum Endocan Levels in Patients with Retinal Vein Occlusion. Retina-Vitreus, Cilt: 29 - Sayı: 3, 238–241. https://ajindex.com/articles/589081

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophtalmol. 1984;98:271-282
  2. Sarrazin S, Adam E, Lyon M, et al. Endocan or endothelial cell specifi c molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cance therapy, Biochim. Biophys. Acta 2006;176:25-37
  3. Lassalle P, Molet S, Janin A, et al. ESM-1 is a novel human endothelial cell-specifi c molecule expressed in lung and regulated by cytokines. J BiolChem 1996;271:20458–64
  4. Kali A, Shetty KS. Endocan: a novel circulating proteoglycan, Indian J. Pharmacol. 2014;46:579-83
  5. Scherpereel A, Depontieu F, Grigoriu B, et al. Crit. CareMed. 2006;34:532-37
  6. Balta I, Balta S, Demirkol S et al. Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk andactivity of disease, Br. J. Dermatol. 2013;169:1066-70
  7. Delehedde M, Devenyns L, Maurage CA et al.Endocan in cancers: a less on from a circulating dermatan sulfate proteoglycan. Int. J. Cell Biol. 2013;705027 8. Gerszten RE, Garcia-Zepeda EA, Lim YC, et al. MCP-1 and IL-8 triggerfi rm adhesion of monocytes to vascular endothelium under fl ow conditions, Nature 1999;398:718-23
  8. Kose M, Emet S, Akpinar TS, et al. Serum endocan level and the severity of coronary artery disease: a pilot study. Angiology 2015;66(8):727-31
  9. Abu El-Asrar AM, Nawaz MI, De Hertogh G, et al. The angiogenic biomarker endocan is upregulated in proliferative diabetic retinopathy and correlates with vascular endothelial growth factor. CurrEyeRes 2015; 40(3):321-31
  10. Balta I, Balta S, Koryurek OM et al. Serum endocan levels as a marker of disease activity in patients with Behçet disease. J. Am. Acad. Dermatol. 2014;70:291- 96.